TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25311333
Drug: Single-arm trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-arm trial intervention including a one-time, half-day educational session with targeted sexual health education, body awareness and relaxation training, and mindfulness-based cognitive therapy strategies, followed by two sessions of tailored telephone counseling.
Study: 12462350
Drug: Porcine secretin
Normalized name: Porcine secretin
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine secretin infusions
Study: 12462350
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human secretin infusions
Study: 9199740
Drug: Timolol (as
Normalized name: timolol (as maleate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (as add-on therapy)
Study: 1756844
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (1.6 mg daily)
Study: 6961762
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg i.v. over 5 min
Study: 6961762
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg orally
Study: 6961762
Drug: Labetalol 400
Normalized name: labetalol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 400 mg orally
Study: 29024278
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor dapagliflozin
Study: 29145894
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of myo‐inositol twice daily for 12 months
Study: 29145894
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo twice daily for 12 months
Study: 23084759
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) treatment with 150g/d of diet
Study: 17238884
Drug: Bilateral infraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral infraorbital nerve block (Group B) with 1 ml 0.25% bupivacaine and 2 ml i.v. saline as control
Study: 15960852
Drug: Self-testing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-testing of blood glucose group; interpreted with nurse-practitioner to inform adjustment of medication
Study: 15960852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with three monthly HbA1c measurements; interpreted with nurse-practitioner
Study: 26436470
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (general)
Study: 12196361
Drug: 8-week VNCOP-B
Normalized name: sennosides, USP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week VNCOP-B plus G-CSF regimen
Study: 12196361
Drug: 12-week VNCOP-B
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week VNCOP-B plus G-CSF regimen
Study: 9465841
Drug: Sirolimus and
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus and cyclosporine administered concomitantly (schedule I)
Study: 9465841
Drug: Sirolimus administered
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus administered 4 hours after cyclosporine (schedule II)
Study: 2649124
Drug: Metoprolol 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 0.07 mg kg‐1 i.v. (9 patients)
Study: 2649124
Drug: Captopril 1
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 1 mg kg‐1 by mouth (11 patients)
Study: 26927900
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron isomaltoside
Study: 26927900
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron isomaltoside infusion
Study: 26927900
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside infusion
Study: 26927900
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside bolus injection
Study: 20696980
Drug: Adherent group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherent group (those who stayed on treatment)
Study: 20696980
Drug: Nonadherent group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadherent group (those who discontinued treatment)
Study: 15813831
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg twice daily
Study: 7544175
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g resistant starch (100 g amylomaize starch)
Study: 2671116
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg three times daily)
Study: 26429655
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 2 mg/kg/d for six months
Study: 23954071
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy (bupropion SR + nicotine lozenge, nicotine patch + nicotine lozenge)
Study: 23954071
Drug: Monotherapy (bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (bupropion SR, nicotine patch, nicotine lozenge)
Study: 15151958
Drug: Hemoglobin responders
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin responders (increase > or =2 g/dl)
Study: 8288662
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg enoxaparin every 12 hours (194 patients)
Study: 8288662
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin once daily (203 patients)
Study: 8288662
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units unfractionated heparin every 8 hours (207 patients)
Study: 27434056
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg L-homoarginine once daily for 4 weeks
Study: 20826244
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, followed by 75 mg daily) in addition to aspirin
Study: 18028997
Drug: Intranasal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal CO2 treatment
Study: 9556010
Drug: Placebo (air)
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (air) treatment
Study: 3816290
Drug: Merieux rubella
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merieux rubella vaccine
Study: 3816290
Drug: Wellcome RA27/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellcome RA27/3 rubella vaccine
Study: 3816290
Drug: Low pre-vaccine
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pre-vaccine titre subjects
Study: 3816290
Drug: High pre-vaccine
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pre-vaccine titre subjects
Study: 29808324
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO), treated once daily at a pressure of 2.0 atm absolute with 100% oxygen.
Study: 29808324
Drug: No hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hyperbaric oxygen therapy (no-HBO), standard arm.
Study: 22119930
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 μg/kg subcutaneously, 12 doses)
Study: 20124207
Drug: Pregabalin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (average daily dosage 385.7 mg/d)
Study: 16202888
Drug: 12 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg/d zoniporide
Study: 12134176
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) treatment for 6 months in group A
Study: 12134176
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) treatment for 1 year in group B
Study: 7539873
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin 20 mg/m2 day 1-5, bleomycin 10 mg/m2 continuous infusion from day 3-7, methotrexate 40 mg/m2 on day 15 and day 22, repeated on day 29 for two cycles)
Study: 7539873
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (surgery + radiation)
Study: 20679501
Drug: Single 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 150 mg dose of caspofungin
Study: 20679501
Drug: Single 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 210 mg dose of caspofungin
Study: 20679501
Drug: Multiple 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple 100 mg doses of caspofungin for 21 days
Study: 19729951
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) for 6 months
Study: 17241413
Drug: BoNTA(2) (Dysport,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNTA(2) (Dysport, Ipsen Ltd.) at dose ratios of 1:2.5, 1:3, or 1:4
Study: 15078741
Drug: Nimesulide, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide, 100 mg orally twice daily
Study: 15078741
Drug: Ibuprofen, 400
Normalized name: Ibuprofen, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 400 mg orally three times daily
Study: 9252814
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (cool packs)
Study: 27575546
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg RAD1901 daily for 28 days
Study: 27575546
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg RAD1901 daily for 28 days
Study: 27575546
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg RAD1901 daily for 28 days
Study: 27575546
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg RAD1901 daily for 28 days
Study: 24223362
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus placebo
Study: 31451367
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with first-line chemotherapy
Study: 16931172
Drug: Kcanrenoate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kcanrenoate (100 mg/day)
Study: 9624787
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate 50 micrograms twice daily via the Diskus inhaler
Study: 9624787
Drug: Terbutaline sulphate
Normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline sulphate 500 micrograms four times daily via the Turbuhaler inhaler
Study: 31599479
Drug: AVB‐S6‐500 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB‐S6‐500 at a dose of 1 mg/kg
Study: 31599479
Drug: AVB‐S6‐500 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB‐S6‐500 at a dose of 5 mg/kg
Study: 31599479
Drug: AVB‐S6‐500 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVB‐S6‐500 at a dose of 10 mg/kg
Study: 19214928
Drug: Steroids given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids given acutely for Bell's palsy
Study: 19214928
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy for Ramsay Hunt syndrome
Study: 19214928
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy for severe cases of Bell's palsy
Study: 19214928
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for Lyme facial neuropathy
Study: 16749407
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg barnidipine
Study: 9272538
Drug: Cardioversion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioversion with subsequent antiarrhythmic drug therapy
Study: 8204701
Drug: Regimen G
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen G (glucose-based TPN)
Study: 31668693
Drug: Anticholinergic drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drug scale (ADS) score assessment
Study: 28805611
Drug: Short I-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short I-D interval (1 mg/kg propofol and 1 μg/kg remifentanil; maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil)
Study: 28805611
Drug: Long I-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long I-D interval (1 mg/kg propofol and 1 μg/kg remifentanil; maintained by continuous infusion of 3 mg/kg/h propofol and 7 μg/kg/h remifentanil)
Study: 25664962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pycnogenol®, roburins, L‐arginine, L‐citrulline
Study: 22682553
Drug: Abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab with unfractionated heparin (UFH)
Study: 15799844
Drug: OCA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA group (omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid)
Study: 12797399
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) with BCNU
Study: 12797399
Drug: Bio-chemotherapy (Bio-CT)
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-chemotherapy (Bio-CT) with BCNU
Study: 12797399
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) without BCNU
Study: 12797399
Drug: Bio-chemotherapy (Bio-CT)
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-chemotherapy (Bio-CT) without BCNU
Study: 10760840
Drug: Deramciclane (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane (0.2 to 50 mg)
Study: 10760840
Drug: Deramciclane (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane (50 to 150 mg)
Study: 619948
Drug: Motival (fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motival (fluphenazine 0.5 mg and nortriptyline 10 mg)
Study: 619948
Drug: Diazepam 7.5
Normalized name: diazepam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 7.5 mg
Study: 619948
Drug: Propranolol 60
Normalized name: propranolol 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 60 mg
Study: 11929322
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oral dose of rivastigmine
Study: 11929322
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous dose of rivastigmine
Study: 24917661
Drug: Single-dose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose metronidazole (2 grams)
Study: 15939560
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormonal therapy (conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate 5 mg/die)
Study: 15939560
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/die
Study: 12826986
Drug: Pregabalin 200
Normalized name: pregabalin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 200 mg tid
Study: 12826986
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg tid
Study: 12826986
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg tid
Study: 6360431
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg, orally)
Study: 30577724
Drug: Lecture on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecture on oral health education (OHE) given by dentists
Study: 30577724
Drug: Lecture on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecture on oral health education (OHE) given by school teachers
Study: 30323581
Drug: YuPingFeng granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: YuPingFeng granules (5 g, three times per day for 1 year)
Study: 20155991
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg with simultaneous discontinuation of the current antipsychotic
Study: 20155991
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks with half the dose after the first 2 weeks
Study: 20155991
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks after maintenance of the current dose for 2 weeks
Study: 17506781
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg at night
Study: 7767514
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 20 mg
Study: 7767514
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 10 mg
Study: 2082945
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion (n = 10)
Study: 2082945
Drug: Labetalol bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol bolus injections of 10 mg every 10 min (n = 10)
Study: 30635141
Drug: Enteral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day)
Study: 30635141
Drug: Sucrose (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (same dose as lactoferrin)
Study: 19400488
Drug: Intraoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ketamine infusion combined with spinal anaesthesia
Study: 10077414
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (when baseline heart rate ≤ 65 beats/min)
Study: 7536623
Drug: GAGPS (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAGPS (25 mg, 0.5 ml)
Study: 2044393
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg intramuscularly up to 4-times a day
Study: 2044393
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg intramuscularly up to 4-times a day
Study: 17633370
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine for supporting healthy energy and strengthening Pi, additional to chemotherapy
Study: 16000607
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin-based)
Study: 15326194
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (single-agent UFT)
Study: 12399205
Drug: Regular-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-dose regimen (5 micro g)
Study: 12399205
Drug: Reduced-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose regimen (2.5 micro g)
Study: 11251757
Drug: Medication grid
Normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication grid intervention
Study: 2974428
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA, 100 mg a day)
Study: 1426844
Drug: Gd‐DTPA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd‐DTPA solution administered per os or per rectum at a concentration of 1 mmol/L
Study: 1426844
Drug: Gd‐DTPA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd‐DTPA solution
Study: 71447
Drug: Leucocyte-migration-inhibition tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-migration-inhibition tests (L.M.T.) against breast-cancer antigen
Study: 30353262
Drug: Subanesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic ketamine infusion (0.5 mg/kg over 40 min)
Study: 30669411
Drug: Wheat Albumin
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat Albumin (WA) 1.5 g
Study: 30173449
Drug: № I
Normalized name: Acetylsalicylic acid
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: № I Empirical Prescription for Chronic Prostatitis (1 dose per day for 8 weeks)
Study: 30173449
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (160 mg bid for 8 weeks)
Study: 2112187
Drug: G‐ORS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐ORS + RF
Study: 2112187
Drug: G‐ORS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐ORS + rice
Study: 2112187
Drug: G‐ORS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐ORS + SF
Study: 465279
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with atenolol and adrenaline
Study: 30590556
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with enduring benefits